The DOI matches its Crossref record; 87 of the 88 references it cites were found in a registry or an index.
A Progressive Mouse Model of Parkinson’s Disease: The Thy1-aSyn (“Line 61”) Mice
Open accessAbstract
Identification of mutations that cause rare familial forms of Parkinson's disease (PD) and subsequent studies of genetic risk factors for sporadic PD have led to an improved understanding of the pathological mechanisms that may cause nonfamilial PD. In particular, genetic and pathological studies strongly suggest that alpha-synuclein, albeit very rarely mutated in PD patients, plays a critical role in the vast majority of individuals with the sporadic form of the disease. We have extensively characterized a mouse model over-expressing full-length, human, wild-type alpha-synuclein under the Thy-1 promoter. We have also shown that this model reproduces many features of sporadic PD, including progressive changes in dopamine release and striatal content, alpha-synuclein pathology, deficits in motor and nonmotor functions that are affected in pre-manifest and manifest phases of PD, inflammation, and biochemical and molecular changes similar to those observed in PD. Preclinical studies have already demonstrated improvement with promising new drugs in this model, which provides an opportunity to test novel neuroprotective strategies during different phases of the disorder using endpoint measures with high power to detect drug effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mouse model utilized in current study is known to reproduce most features of synucleinopathies, including neuropathology and deficits in motor and non-motor function (46).”
From LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies (2020) · cites this paper as [46]
Experimental — accuracy not yet measuredIn the citing paper
“Importantly, ASO (overexpressing a-synuclein under Thy1 promoter) mouse model of PD develops progressive deficits in motor function as well as in gut motility (182, 183).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [182]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WGCNA: an R package for weighted correlation network analysis
Langfelder, P., & Horvath, S. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-559 · Cited by 27,252
Harrison's Principles of Internal Medicine.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-499_2 · Cited by 12,528
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Harrison's principles of internal medicine
(2008) · Choice Reviews Online · doi:10.5860/choice.46-0330 · Cited by 3,072
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Masliah, E., Rockenstein, E. M., Veinbergs, I., Mallory, M. E., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,779
Braak, H., de Vos, R. A. I., Bohl, J., & Del Tredici, K. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2005.11.012 · Cited by 1,354
Brochard, V., Combadière, B., Prigent, A., Laouar, Y., Perrin, A., Beray-Berthat, V., Bonduelle, O., Alvarez-Fischer, D., Callebert, J., Launay, J.-M., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36470 · Cited by 1,172
Parkinson's disease: a dual‐hit hypothesis
Hawkes, C. H., Del Tredici, K., & Braak, H. (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00874.x · Cited by 1,021
Research works printed but not linked: 6
- Hean, 2010, Mice overexpressing human alpha synuclein (Thy1-aSyn) show dopamine loss, catalepsy and severe motor deficits partially rescued by L-DOPA at 14 months of age, Neurosci Abstr, 750
- Torres, 2010, Mice overexpressing human alpha synuclein under the Thy1-promotor show increased fear conditioning and altered responses in anxiety related behavior, Neurosci Abstr, 750
- Mulligan, 2008, Mice overexpressing human wildtype alpha-synuclein under the Thy-1 promoter exhibit anomalies in behavioral tests of anxiety, Neurosci Abstr, 742
- Richter, 2011, Transcriptome network and pathway analyses reveal early alterations in dopaminergic neurons of mice overexpressing human wild-type alpha-synuclein (Thy1-aSyn), Neurosci Abstr, 357
- Richter, 2010, The cholesterol-oximes TRO19622 and TRO40303 affect motor function, olfaction, and alpha synuclein aggregation in mice overexpressing human alpha synuclein under the Thy1 promoter, Neurosci Abstr, 750
- Lemesre, 2010, The glucocerebrosidase pharmacological chaperone afegostat-tartrate (AT2101) partially improves motor and olfactory function and alters the size of alpha-synuclein inclusions in mice overexpressing alpha-synuclein, Neurosci Abstr, 750
Cited by
Sorted by citations
Items 101–200 of 346
Richter, F., Gabby, L. C., McDowell, K. A., Mulligan, C. K., Rosa, K. D. L., Sioshansi, P. C., Mortazavi, F., Cely, I., Ackerson, L. C., Tsan, L., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.11.015 · Cited by 46
Orr, A. L., Rutaganira, F. U., de Roulet, D., Huang, E. J., Hertz, N. T., Shokat, K. M., & Nakamura, K. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.04.006 · Cited by 47
Autonomic dysfunction in Parkinson disease and animal models
Metzger, J. M., & Emborg, M. E. (2019) · Clinical Autonomic Research · doi:10.1007/s10286-018-00584-7 · Cited by 46
Gut microbes augment neurodegeneration
Erny, D., & Prinz, M. (2017) · Nature · doi:10.1038/nature21910 · Cited by 45
Environmental triggers of Parkinson's disease – Implications of the Braak and dual-hit hypotheses
Chen, H., Wang, K., Scheperjans, F., & Killinger, B. A. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105601 · Cited by 45
Pradhan, S., & Andreasson, K. I. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.12.008 · Cited by 43
Magen, I., Ostritsky, R., Richter, F., Zhu, C., Fleming, S. M., Lemesre, V., Stewart, A. J., Morimoto, B. H., Gozes, I., & Chesselet, M. (2014) · Pharmacology Research & Perspectives · doi:10.1002/prp2.65 · Cited by 43
Recapitulating Parkinson's disease pathology in a three-dimensional human neural cell culture model
Taylor-Whiteley, T. R., Maitre, C. L. L., Duce, J. A., Dalton, C., & Smith, D. P. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.038042 · Cited by 43
Iba, M., Kim, C., Kwon, S., Szabo, M. P., Horan-Portelance, L., Peer, C. J., Figg, W. D., Reed, X., Ding, J., Lee, S., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abq6089 · Cited by 42
Genetically engineered animal models of Parkinson's disease: From worm to rodent
Breger, L. S., & Armentero, M. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14300 · Cited by 45
Baroreflex dysfunction in Parkinson’s disease: integration of central and peripheral mechanisms
Sabino‐Carvalho, J. L., Falquetto, B., Takakura, A. C. T., & Vianna, L. C. (2021) · Journal of Neurophysiology · doi:10.1152/jn.00548.2020 · Cited by 40
Hong, H., Wang, Y., Menard, M. A., Buckley, J. A., Zhou, L., Volpicelli‐Daley, L. A., Standaert, D. G., Qin, H., & Benveniste, E. N. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03210-8 · Cited by 44
Modeling Parkinson's disease‐related symptoms in alpha‐synuclein overexpressing mice
Aniszewska, A., Bergström, J. J. E., Ingelsson, M., & Ekmark‐Lewén, S. (2022) · Brain and Behavior · doi:10.1002/brb3.2628 · Cited by 39
Zhu, Q., Song, J., Chen, J.-Y., Yuan, Z., Liu, L., Xie, L., Liao, Q., Ye, R. D., Chen, X., Yan, Y., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.03.011 · Cited by 39
Price, D. L., Khan, A., Angers, R. C., Cardenas, A., Prato, M. K., Bani, M., Bonhaus, D. W., Citron, M., & Biere, A. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00552-7 · Cited by 45
Kikuchi, T., Morizane, A., Doi, D., Okita, K., Nakagawa, M., Yamakado, H., Inoue, H., Takahashi, R., & Takahashi, J. B. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.24014 · Cited by 41
Comprehensive Perspectives on Experimental Models for Parkinson’s Disease
Ke, M., Chong, C., Zhu, Q., Zhang, K., Cai, C.-Z., Lu, J., Qin, D., & Su, H. (2021) · Aging and Disease · doi:10.14336/ad.2020.0331 · Cited by 41
Geertsma, H. M., Suk, T. R., Ricke, K. M., Horsthuis, K., Parmasad, J.-L. A., Fisk, Z. A., Callaghan, S. M., & Rousseaux, M. W. C. (2022) · Human Molecular Genetics · doi:10.1093/hmg/ddac035 · Cited by 35
Therapeutic strategies in Parkinson's disease: what we have learned from animal models
Valadas, J. S., Vos, M. H., & Verstreken, P. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12577 · Cited by 44
Schommer, J., Marwarha, G., Nagamoto‐Combs, K., & Ghribi, O. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00552 · Cited by 38
Impact of DHA intake in a mouse model of synucleinopathy
Coulombe, K., Kerdiles, O., Tremblay, C., Émond, V., Lebel, M., Boulianne, A.-S., Plourde, M., Cicchetti, F., & Calon, F. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.12.002 · Cited by 38
Khairnar, A., Kučerová, J., Szabó, N., Dražanová, E., Arab, A., Hutter‐Paier, B., Neddens, J., Latta, P., Starčuk, Z., & Rektorová, I. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.11.027 · Cited by 37
Sleep Disorders in Rodent Models of Parkinson’s Disease
Medeiros, D. D. C., Lopes‐Aguiar, C., Moraes, M. F. D., & Fisone, G. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01414 · Cited by 38
Targeting alpha-synuclein via the immune system in Parkinson's disease: Current vaccine therapies
Fleming, S. M., Davis, A., & Simons, E. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108870 · Cited by 37
Tamburrino, A., Churchill, M. J., Wan, O. W., Colino‐Sanguino, Y., Ippolito, R., Bergstrand, S., Wolf, D. A., Herz, N. J., Sconce, M. D., Björklund, A., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0263-6 · Cited by 41
Gao, G., Wang, Z., Lu, L., Duan, C., Wang, X., & Yang, H. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.057 · Cited by 36
Cuvelier, E., Méquinion, M., Leghay, C., Sibran, W., Stiévenard, A., Sarchione, A., Bonte, M.-A., Vanbesien-Mailliot, C., Viltart, O., Saitoski, K., et al. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00321 · Cited by 40
Farrerol attenuates MPP+‐induced inflammatory response by TLR4 signaling in a microglia cell line
Cui, B., Guo, X., You, Y., & Fu, R. (2019) · Phytotherapy Research · doi:10.1002/ptr.6307 · Cited by 35
Evaluation of Carnosine Intervention in the Thy1-aSyn Mouse Model of Parkinson's Disease
Bermúdez, M.-L., Seroogy, K. B., & Genter, M. B. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.05.026 · Cited by 35
Sanchez, G. M., Varaschin, R. K., Büeler, H., Marcogliese, P. C., Park, D. S., & Trudeau, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094826 · Cited by 41
Subramaniam, S., Magen, I., Bove, N., Zhu, C., Lemesre, V., Dutta, G., Elias, C. J., Lester, H. A., & Chesselet, M. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.05.018 · Cited by 33
Nimmo, J., Smith, H., Wang, C. Y., Teeling, J. L., Nicoll, J. A. R., Verma, A. K., Dodart, J., Liu, Z., Feng, L., & Carare, R. O. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02381-5 · Cited by 32
Richter, F., Gao, F., Medvedeva, V. P., Lee, P. C., Bove, N., Fleming, S. M., Michaud, M., Lemesre, V., Patassini, S., Rosa, K. D. L., et al. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.05.012 · Cited by 33
Zhu, C., Bilousova, T. V., Focht, S., Jun, M., Elias, C. J., Melnik, M., Chandra, S., Campagna, J. J., Cohn, W., Hatami, A., et al. (2021) · Molecular Brain · doi:10.1186/s13041-021-00776-9 · Cited by 39
Morpho‐Functional Changes of Nigral Dopamine Neurons in an α‐Synuclein Model of Parkinson's Disease
Ledonne, A., Cenere, M. M., Paldino, E., D’Angelo, V., D’Addario, S. L., Casadei, N., Nobili, A., Berretta, N., Fusco, F. R., Ventura, R., et al. (2022) · Movement Disorders · doi:10.1002/mds.29269 · Cited by 32
Iba, M., Kim, C., Florio, J. B., Mante, M., Adame, A., Rockenstein, E. M., Kwon, S., Rissman, R. A., & Masliah, E. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00286 · Cited by 33
RetractedMiller, S., Campbell, C. E., Jimenez-Corea, H. A., Wu, G., & Logan, R. A. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.824191 · Cited by 34
Fathi, M., Vakili, K. G., Yaghoobpoor, S., Qadirifard, M. S., Kosari, M., Naghsh, N., Taei, A. A., Klegeris, A., Dehghani, M., Bahrami, A., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.855776 · Cited by 35
Lai, T. T., Gericke, B., Feja, M., Conoscenti, M. A., Zelikowsky, M., & Richter, F. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00547-4 · Cited by 34
Apoptosis signal-regulating kinase 1 modulates the phenotype of α-synuclein transgenic mice
Lee, K. W., Woo, J.-M., Im, J. Y., Park, E. S., He, L., Ichijo, H., Junn, E., & Mouradian, M. M. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.07.034 · Cited by 32
Novel models for Parkinson’s disease and their impact on future drug discovery
Trigo‐Damas, I., del Rey, N. L., & Blesa, J. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1428556 · Cited by 31
Brekk, O. R., Moskites, A., Ole Isacson, A., & Hallett, P. J. (2018) · Scientific Reports · doi:10.1038/s41598-018-33474-z · Cited by 33
Are There Potential Applications of Fecal Microbiota Transplantation beyond Intestinal Disorders?
Zhou, Y., Xu, H., Huang, H., Li, Y., Chen, H., He, J., Du, Y., Chen, Y., Zhou, Y., & Nie, Y. (2019) · BioMed Research International · doi:10.1155/2019/3469754 · Cited by 32
A glutaminyl cyclase-catalyzed α-synuclein modification identified in human synucleinopathies
Hartlage‐Rübsamen, M., Bluhm, A., Moceri, S., Machner, L., Köppen, J., Schenk, M., Hilbrich, I., Holzer, M., Weidenfeller, M., Richter, F., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02349-5 · Cited by 31
Microbes and Parkinson’s disease: from associations to mechanisms
Cannon, T., & Gruenheid, S. (2022) · Trends in Microbiology · doi:10.1016/j.tim.2022.01.004 · Cited by 33
More, S. V., Kumar, H., Kim, I., Koppula, S., Kim, B.-W., & Choi, D. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/18715273113129990059 · Cited by 31
Nonmotor Symptoms in Experimental Models of Parkinson's Disease
Titova, N., Schapira, A. H. V., Chaudhuri, К. R., Qamar, M. A., Катунина, Е. А., & Jenner, P. G. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2017.05.018 · Cited by 30
Targeted de-repression of neuronal Nrf2 inhibits α-synuclein accumulation
Baxter, P. S., Márkus, N. M., Dando, O., He, X., Al-Mubarak, B. R., Qiu, J., & Hardingham, G. E. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03507-z · Cited by 31
Torres, E. R. S., Stanojlović, M., Zelikowsky, M., Bonsberger, J., Hean, S., Mulligan, C. K., Baldauf, L., Fleming, S. M., Masliah, E., Chesselet, M., et al. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105478 · Cited by 28
Frahm, S., Melis, V., Horsley, D., Rickard, J. E., Riedel, G., Fadda, P., Scherma, M., Harrington, C. R., Wischik, C. M., Theuring, F., et al. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.11.025 · Cited by 28
Jackson, A., Engen, P. A., Forsyth, C. B., Shaikh, M. W., Naqib, A. D., Wilber, S., Frausto, D. M., Raeisi, S., Green, S. J., Bradaric, B. D., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.882628 · Cited by 27
Rauschenberger, L., Behnke, J. K., Grotemeyer, A., Knörr, S., Volkmann, J., & Ip, C. W. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105798 · Cited by 29
Magen, I., Torres, E. R. S., Dinh, D., Chung, A., Masliah, E., & Chesselet, M. (2015) · Journal of Parkinson s Disease · doi:10.3233/jpd-140503 · Cited by 27
RNA Interference of Human α-Synuclein in Mouse
Kim, Y.-C., Miller, A., Lins, L. C. R. F., Han, S.-W., Keiser, M. S., Boudreau, R. L., Davidson, B. L., & Narayanan, N. S. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00013 · Cited by 28
Multiple System Atrophy: Pathology, Pathogenesis, and Path Forward
Ndayisaba, A., Halliday, G. M., & Khurana, V. (2024) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-051122-104528 · Cited by 31
Behavioral analysis of motor and non-motor impairment in rodent models of Parkinson's disease
Sheta, R., Bérard, M., Musiol, D., Martínez-Drudis, L., & Oueslati, A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1464706 · Cited by 26
Rat Models of Vocal Deficits in Parkinson’s Disease
Krasko, M. N., Hoffmeister, J. D., Schaen‐Heacock, N. E., Welsch, J. M., Kelm‐Nelson, C. A., & Ciucci, M. R. (2021) · Brain Sciences · doi:10.3390/brainsci11070925 · Cited by 26
Reduction of αSYN Pathology in a Mouse Model of PD Using a Brain-Penetrating Bispecific Antibody
Roshanbin, S., Julku, U. H., Xiong, M., Eriksson, J., Masliah, E., Hultqvist, G., Bergström, J. J. E., Ingelsson, M., Syvänen, S., & Sehlin, D. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071412 · Cited by 30
Doublecortin-like Kinase 1 Regulates α-Synuclein Levels and Toxicity
Vázquez-Vélez, G. E., Gonzales, K. A., Revelli, J.-P., Adamski, C. J., Alavi Naini, F., Bajić, A., Craigen, E., Richman, R., Heman-Ackah, S. M., Wood, M. J. A., et al. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.1076-19.2019 · Cited by 22
“This line overexpresses WT human SNCA at 10-fold normal levels throughout the brain (Rockenstein et al., 2002; Chesselet et al., 2012).”
BackgroundNonmotor Parkinson's and Future Directions
Titova, N., & Chaudhuri, К. R. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2017.05.017 · Cited by 25
Locomotor differences in mice expressing wild-type human α-synuclein
Giraldo, G., Brooks, M., Giasson, B. I., & Janus, C. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.01.020 · Cited by 25
Khairnar, A., Kučerová, J., Dražanová, E., Szabó, N., Latta, P., Arab, A., Hutter‐Paier, B., Havas, D., Windisch, M., Šulcová, A., et al. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13500 · Cited by 25
Xiong, M., Roshanbin, S., Rokka, J., Schlein, E., Ingelsson, M., Sehlin, D., Eriksson, J., & Syvänen, S. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118302 · Cited by 24
Sharma, M., Kaur, J., Rakshe, S., Sharma, N., Khunt, D., & Khairnar, A. (2021) · Neurotoxicity Research · doi:10.1007/s12640-021-00436-9 · Cited by 24
Molecular Tweezers: Supramolecular Hosts with Broad-Spectrum Biological Applications
Shahpasand‐Kroner, H., Siddique, I. A., Malik, R., Linares, G. R., Ivanova, M. I., Ichida, J. K., Weil, T., Münch, J., Sánchez‐García, E., Klärner, F., et al. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000654 · Cited by 25
Bermúdez, M.-L., Skelton, M. R., & Genter, M. B. (2018) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2018.08.002 · Cited by 23
Parsons, C. G. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.08.027 · Cited by 22
Lobb, C. J., Zaheer, A., Smith, Y., & Jaeger, D. (2013) · Journal of Neurophysiology · doi:10.1152/jn.00441.2013 · Cited by 22
Patterns of diffusion kurtosis changes in Parkinson's disease subtypes
Minsterová, A. Š., Klobušiaková, P., Pies, A., Galáž, Z., Mekyska, J., Novakova, L., Elfmarková, N., & Rektorová, I. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.10.032 · Cited by 22
Sex and Age Differences in a Progressive Synucleinopathy Mouse Model
Lamontagne‐Proulx, J., Coulombe, K., Morissette, M., Rieux, M., Calon, F., Paolo, T. D., & Soulet, D. (2023) · Biomolecules · doi:10.3390/biom13060977 · Cited by 21
Dirr, E. R., Ekhator, O. R., Blackwood, R., Holden, J. G., Masliah, E., Schultheis, P. J., & Fleming, S. M. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.01.029 · Cited by 23
Roshanbin, S., Aniszewska, A., Gumucio, A., Masliah, E., Erlandsson, A., Bergström, J. J. E., Ingelsson, M., & Ekmark‐Lewén, S. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.01.010 · Cited by 24
Joseph, T. P., Jagadeesan, N., Sai, L., Lin, S. L., Sahu, S. S., & Schachner, M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00458 · Cited by 20
Schreiber, C. S., Wiesweg, I., Stanelle‐Bertram, S., Beck, S., Kouassi, N. M., Schaumburg, B., Gabriel, G., Richter, F., & Käufer, C. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105191 · Cited by 21
Parkinson’s disease: what the model systems have taught us so far
Ghatak, S., Trudler, D., Dolatabadi, N., & Ambasudhan, R. (2018) · Journal of Genetics · doi:10.1007/s12041-018-0960-6 · Cited by 20
Khairnar, A., Latta, P., Dražanová, E., Kučerová, J., Szabó, N., Arab, A., Hutter‐Paier, B., Havas, D., Windisch, M., Šulcová, A., et al. (2015) · Neurotoxicity Research · doi:10.1007/s12640-015-9537-9 · Cited by 20
Lau, K., Porschen, L. T., Richter, F., & Gericke, B. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106298 · Cited by 18
Feja, M., Drath, I., Weiß, S., Ewe, A., Gericke, B., Outeiro, T. F., Stefanis, L., Aigner, A. M., & Richter, F. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102671 · Cited by 19
α-synuclein overexpression and the microbiome shape the gut and brain metabolome in mice
Morais, L. H., Boktor, J. C., MahmoudianDehkordi, S., Kaddurah‐Daouk, R., & Mazmanian, S. K. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00816-w · Cited by 24
Gerstenberger, J., Bauer, A., Helmschrodt, C., Richter, A., & Richter, F. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.02.017 · Cited by 18
Brown-Leung, J. M., Baker, L. S., Seroogy, K. B., & Genter, M. B. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00096 · Cited by 18
da Silva, M. I. O., Santejo, M., Babcock, I. W., Magalhães, A., Minamide, L. S., Won, S.-J., Castillo, E., Gerhardt, E., Fahlbusch, C., Swanson, R. A., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06630-9 · Cited by 17
The gut-brain connection in the pathogenicity of Parkinson disease: Putative role of autophagy
Kakoty, V., Sarathlal, K. C., Dubey, S. K., Yang, C. H., Kesharwani, P., & Taliyan, R. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.135865 · Cited by 18
Khan, A., Johnson, R., Wittmer, C., Maile, M., Tatsukawa, K. J., Wong, J. L., Gill, M. B., Stocking, E. M., Natala, S. R., Paulino, A., et al. (2021) · Brain · doi:10.1093/brain/awab214 · Cited by 17
Synaptic vesicle-omics in mice captures signatures of aging and synucleinopathy
Gao, V., Chlebowicz, J., Gaskin, K., Briano, J. A., Komer, L. E., Pineda, A., Jhalani, S., Ahmad, S., Uwaifo, E., Black, L. S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59441-7 · Cited by 18
Bernard, K., Mota, J. A., Wene, P. V., Corenblum, M. J., Saez, J. L., Bartlett, M. J., Heien, M. L., Doyle, K. P., Polt, R. L., Hay, M., et al. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.114926 · Cited by 15
Khairnar, A., Kučerová, J., Arab, A., Hadjistyllis, C., Minsterová, A. Š., Shang, Q., Chovsepian, A., Dražanová, E., Szabó, N., Starčuk, Z., et al. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15449 · Cited by 15
Characterizing the Retinal Phenotype of the Thy1-h[A30P]α-syn Mouse Model of Parkinson’s Disease
Veys, L., Devroye, J., Lefevere, E., Cools, L., Vandenabeele, M., & Groef, L. D. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.726476 · Cited by 17
Rabl, R., Horvath, A., Breitschaedel, C., Flunkert, S., Roemer, H., & Hutter‐Paier, B. (2016) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2016.10.006 · Cited by 16
Are we listening to everything the PARK genes are telling us?
Benson, D. L., & Huntley, G. W. (2019) · The Journal of Comparative Neurology · doi:10.1002/cne.24642 · Cited by 17
Kim, J. J., Daadi, E. W., Oh, T. T., Daadi, E. S., & Daadi, M. M. (2022) · Genes · doi:10.3390/genes13111937 · Cited by 14
Double‐Edged Effects of Venglustat on Behavior and Pathology in Mice Overexpressing α‐Synuclein
Schidlitzki, A., Stanojlović, M., Fournier, C., Käufer, C., Feja, M., Gericke, B., Garzotti, M., Welford, R. W. D., Steiner, M. A., Angot, É., et al. (2023) · Movement Disorders · doi:10.1002/mds.29398 · Cited by 15
Gut-to-brain spreading of pathology in synucleinopathies: A focus on molecular signalling mediators
Schmitt, V., Masanetz, R. K., Weidenfeller, M., Ebbinghaus, L. S., Süß, P., Rosshart, S. P., von Hörsten, S., Zunke, F., Winkler, J., & Xiang, W. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114574 · Cited by 16
Seeking progress in disease modification in Parkinson disease
Lungu, C., Cedarbaum, J. M., Dawson, T. M., Dorsey, E. R., Faraco, C., Federoff, H. J., Fiske, B. K., Fox, R. J., Goldfine, A. M., Kieburtz, K. D., et al. (2021) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2021.09.006 · Cited by 15
Immunolocalization of human alpha-synuclein in the Thy1-aSyn (“Line 61”) transgenic mouse line
Delenclos, M., Carrascal, L., Jensen, K., & Romero‐Ramos, M. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.07.042 · Cited by 16
Sinnige, T., Stroobants, K., Dobson, C. M., & Vendruscolo, M. (2020) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583520000025 · Cited by 18
Sinnige, T., Stroobants, K., Dobson, C. M., & Vendruscolo, M. (2020) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583520000104 · Cited by 15
Schreiber, C. S., Ramil, L. N., Bieligk, J., Meineke, R., Rimmelzwaan, G. F., Käufer, C., & Richter, F. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.05.021 · Cited by 15
Deng, Z., Li, L., Jing, Z., Luo, X., Yu, F., Zeng, W., Bi, W., & Zou, J. (2024) · Environment International · doi:10.1016/j.envint.2024.108806 · Cited by 14
Leveraging animal models to understand non-motor symptoms of Parkinson's disease
Wichmann, T., Nelson, A., Torres, E. R. S., Svenningsson, P., & Marongiu, R. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106848 · Cited by 14
Metadata
- Authors
- Chesselet, M.-F., Richter, F., Zhu, C., Magen, I., Watson, M. B., & Subramaniam, S. R.
- Affiliations
- University of California, Los Angeles (US)
- Venue
- Neurotherapeutics
- Publisher
- Elsevier BV
- Published
- 2012-04
- Volume
- 9
- Issue
- 2
- Pages
- 297-314
- ISSN
- 1878-7479 (ISSN-L)
- PMC
- PMC3337020
- OpenAlex
- W2169324918
- Cited by
- 346
- References
- 88
- Citations by year
- 2026: 18 · 2025: 38 · 2024: 38 · 2023: 30 · 2022: 33 · 2021: 40 · 2020: 23 · 2019: 20 · 2018: 26 · 2017: 26 · 2016: 12 · 2015: 13 · 2014: 21 · 2013: 5 · 2012: 3
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Neurotherapeutics (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Neurological Disorders and Stroke (P50-NS 38367, P50NS038367)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkinson's disease, alpha-synuclein, mouse model, sporadic Parkinson's disease, dopamine release, striatum, motor impairment, neuroinflammation, neuroprotection, preclinical drug testing, alpha-synuclein pathology
- MeSH terms
- Animals, Disease Models, Animal, Humans, Mice, Neurologic Mutants, Parkinson Disease, Promoter Regions, Genetic, Disease Progression, Mice, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
